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Summary box
 ► Horizon Europe, the new European Union Research 
and Innovation Framework for the period 2021–
2027, will play an important role for health research 
globally.
 ► The overall visibility of Global Health and the partic-
ipation of low- income and middle- income countries 
(LMICs) have declined at EU level in recent years, 
and Horizon Europe barely mentions Global Health 
and LMICs.
 ► Innovation is equated with industrial competitive-
ness of European companies rather than effective 
and cost- saving innovations that could benefit EU 
countries and LMICs alike.
 ► The relative budget allocated to health shows a de-
cline from 10% in the current framework, Horizon 
2020, to 8% in Horizon Europe.
 ► More international, transdisciplinary and equitable 
research collaboration and broader access to Global 
Health research funding is needed, especially for 
LMICs, to ensure that future health research is based 
on the Sustainable Development Goals and address-
es the major health challenges the world is facing.
AbSTrACT
Global Health has not featured as prominently in the 
European Union (EU) research agenda in recent years 
as it did in the first decade of the new millennium, and 
participation of low- income and middle- income countries 
(LMICs) in EU health research has declined substantially. 
The Horizon Europe Research and Innovation Framework 
adopted by the European Parliament in April 2019 for the 
period 2021–2027 will serve as an important funding 
instrument for health research, yet the proposed health 
research budget to be finalised towards the end of 2019 
was reduced from 10% in the current framework, Horizon 
2020, to 8% in Horizon Europe. Our analysis takes the 
evolvement of Horizon Europe from the initial framework 
of June 2018 to the framework agreed on in April 2019 
into account. It shows that despite some improvements in 
terms of Global Health and reference to the Sustainable 
Development Goals, European industrial competitiveness 
continues to play a paramount role, with Global Health 
research needs and relevant health research for LMICs 
being only partially addressed. We argue that the globally 
interconnected nature of health and the transdisciplinary 
nature of health research need to be fully taken into 
account and acted on in the new European Research 
and Innovation Framework. A facilitated global research 
collaboration through Horizon Europe could ensure that 
Global Health innovations and solutions benefit all parts of 
the world including EU countries.
InTroduCTIon
Global Health evolved from the concepts of 
public1 and international health2 3 to form 
a ‘system- based, ecological and transdisci-
plinary approach to research, education, 
and practice which seeks to provide innova-
tive, integrated, and sustainable solutions 
to address complex health problems across 
national boundaries and improve health for 
all’ (p 155).4 Important components of Global 
Health include health equity, a focus on 
health issues transcending national borders, 
determinants of health, interdisciplinary and 
international collaboration and a ‘health for 
all’ approach.2–9
Global Health aims to overcome the 
national–international divide9 and that 
between high- income countries (HICs) and 
low- income and middle- income countries 
(LMICs) through mutual exchange and part-
nership, including joint funding, agenda 
setting, planning and implementation.2 3 10 
In doing so, Global Health aims to address 
the 10/90 gap,11 the disparity between global 
health research spending and disease burden 
in LMICs. However, the formation of genuine 
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research partnerships remains a challenge,3 10 12 as does 
the prioritisation of research targeted at high disease 
burden populations.2 These challenges are highlighted 
by the increasing mobility of the global population13 14 
and the rapid rise of non- communicable diseases with 
complex social determinants that require transdisci-
plinary scientific approaches4 15 and innovative solu-
tions.16 17
This paper emanated from a transdisciplinary meeting 
of European Global Health research institutes with a 
non- governmental global development organisation in 
Brussels in July 2018. The 22 participants in this two- day 
meeting represented European Global Health researchers 
from Belgium (University of Antwerp), Germany 
(Ruprecht- Karls- University, Heidelberg, Ludwig- 
Maximilians- University, Munich), Italy (University of 
Milan), Spain (University of Barcelona), Sweden (Lund 
University), Switzerland (University of Geneva), the Neth-
erlands (University of Amsterdam, University of Leiden, 
Utrecht University), the UK (Imperial College London, 
University College London, University of Oxford) and a 
non- governmental organisation (NGO) for global devel-
opment, Deutsche Stiftung Weltbevölkerung (DSW). A 
Future Search Conference methodology18–20 was used to 
assess developments in Global Health at individual insti-
tutions, across Europe and globally. With the European 
Commission publishing a new European Research and 
Innovation (R&I) Framework, Horizon Europe, partici-
pants analysed European health R&I priorities based on 
Global Health challenges and with the aim to strengthen 
Global Health considerations in this framework. Negotia-
tions between the Council of the European Union (EU) 
and the European Parliament led to modifications in the 
Horizon Europe Framework. The negotiating process 
was informed by the positions of various actors—private 
sector, NGOs and academic institutions—including 
that of the European Global Health Research Institutes 
Network (EGHRIN), a network formed at the Brussels 
meeting in July 2018, see https//eghrin- eu. To illus-
trate important text and structural changes in Horizon 
Europe with regard to Global Health, this paper refers 
to the initially proposed framework and regulation docu-
ments by the European Commission of June 201821–24 as 
well as subsequent versions in late 201825 26 leading to the 
documents agreed on by EU institutions and approved 
by the European Parliament in April 2019.27 28 The EU 
R&I Framework is analysed and appraised from a Global 
Health perspective and with reference to the Sustainable 
Development Goal (SDG) framework.29
Eu EfforTS on GlobAl HEAlTH In THE lAST dECAdE
Global Health came to prominence on the European 
agenda with the EU‘s first health strategy and policy 
framework in 2007 and Council Conclusions on Global 
Health in 2010.30 The 2010 Council Conclusions set out 
to advance a visionary Global Health agenda focused on 
strengthening collaborative research capacity; developing 
affordable medical products; dissociating Research & 
Development (R&D) costs from intellectual property 
considerations; ensuring that access to knowledge and 
tools form part of the R&D agenda; and strengthening 
health systems to measure progress on the social deter-
minants of health.31 Yet, instead of being the starting 
point for greater Global Health research engagement, 
the EU Communication and Council Conclusions largely 
remained a statement rather than a plan for action30 and 
few member states developed their own Global Health 
policies.32
The EU Communication on its role in Global Health33 
emphasised the aspect of ‘protection against Global 
Health threats’ (p 2). Protection was, however, mainly 
defined in terms of strengthening ‘global and third coun-
tries’ national capacities of early prediction, detection 
and response to Global Health threats’ (p 8) rather than 
focusing on cross- border health threats, which became 
more prominent in recent publications of the EU.27 34 
This led to the question of whom health security is for35 36 
or even what it should entail37 or how ‘security’ should 
be defined and specified.38 Global Health strategies with 
a self- interested security concern can also be perceived in 
the policies of member states such as the UK, Germany 
and France.32 Security concerns relate to a regionalisa-
tion of local epidemic outbreaks, the threat of terrorism 
from impoverished regions, and conflict over resources 
due to climate change, to name a few.39 The heightened 
concern for security and the persistent after- effects of 
the 2008 financial crisis led to Europe’s 2020 strategy, 
which focused primarily on job creation and economic 
growth.40
Germany used its presidencies of the G7 and G20 
summits in 2015 and 2017 to give more prominence to 
Global Health.41 42 Yet, Global Health has largely fallen 
off the EU research agenda.22 27 28
nEw EuropEAn r&I frAmEwork—HorIzon EuropE
Horizon Europe lists health as one of six clusters in ‘Global 
Challenges and European Industrial Competitiveness’,27 
the second pillar of the programme. The other two 
pillars are ‘Excellent Science’ and ‘Innovative Europe’,27 
see figure 1. The health cluster is divided into six priority 
areas: health throughout the life course; environmental 
and social health determinants; non- communicable 
and rare diseases; infectious diseases, including poverty- 
related and neglected diseases (PRND); tools, technolo-
gies and digital solutions for health and care, including 
personalised medicine, and healthcare systems.28
Horizon 2020 is the EU’s current R&I Framework 
Programme (2014–2020) with a budget of €80 billion34 43 
with 10% earmarked for health.34 The European Commis-
sion proposed the successor programme Horizon Europe 
in 2018, with a budget of €94.1 billion for 2021–2027 
including €7.7 billion, or 8%, earmarked for health.23 
The draft documents were discussed by the Council of 
the EU and the European Parliament and altered with 
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Figure 1 Horizon Europe R&I Framework based on the Common Understanding reached between Council and European 
Parliament on 27 March 2019 and the Partial General Agreement of 15 April 2019. Italicized text indicates changes in the 
Framework agreed upon by EU institutions in 2019.
some improvements on Global Health language and 
concepts27 28 while at the same time emphasising Euro-
pean innovations, see figure 1. The Council upheld multi-
dimensionality in addressing global challenges, among 
others through R&I missions,25 28 yet did not increase the 
budget proposal of the European Commission of €94 
billion. Contrary to the Council, the European Parliament 
proposed an overall research budget for Horizon Europe 
of €120 billion,26 with the health cluster receiving 8.16% 
or €9.79 billion of the overall budget.44 The budget was 
not part of the final Horizon Europe Framework of April 
2019 and will be negotiated as part of the multiannual 
financial framework in 2019.45
AnAlySIS of Eu r&I frAmEwork
What follows is a European Global Health institutes’ anal-
ysis of Global Health issues in the current and previous 
Horizon Europe frameworks.21–24 27 28 46 47 SDGs and 
industrial competitiveness and innovation, which are 
central themes in the Horizon Europe Framework, are 
also considered in this analysis. Further themes such as 
funding, health systems, environmental and social health 
determinants and more detailed information on Global 
Health, PRND, LMICs, networking and participation are 
listed in the online supplementary table 1.
SdGs, Global Health, one Health and Horizon Europe
The move from the Millennium Development Goals to 
the SDGs calls for interdisciplinary and transdisciplinary 
approaches29 48 and thus can be seen as strengthening 
Global Health endeavours. Infectious and non- 
communicable diseases and environmental health risks 
are a worldwide concern and not limited to individual 
countries or regions;49 an adequate response therefore 
needs to be global and interconnected. The Horizon 
Europe Framework links the health cluster only to SDGs 3 
(good health and well- being)27 and 13 (climate action);27 
its interconnectedness with other SDGs is not specifi-
cally mentioned despite the EU’s ‘health in all policies’ 
approach of 2006 which is lagging behind in implemen-
tation.50 In the course of the negotiations of the Horizon 
Europe Framework, SDG references increased from 
4522–24 to 57,27 28 yet the health cluster continues to be 
linked only to ‘health’ and ‘climate action’.27 Locating 
health at the centre of all other SDGs and linking health 
aspects with all other clusters in the Horizon Europe 
Framework would underscore the importance of Global 
Health in working towards the achievement of the SDGs 
and the contribution of the SDGs to Global Health51 
with a view to achieving planetary health.6 This would 
incorporate a One Health approach, which is mentioned 
several times in the Horizon Europe Framework27 in 
connection with antimicrobial resistance (AMR), an area 
for which the EU is an important global actor.52 While 
Horizon Europe acknowledges that ‘health challenges 
are complex, interlinked and global’ (p 19),22 the final 
framework has placed the term ‘Global Health’ in the 
context of infectious diseases.27 Notwithstanding the 
importance of infectious diseases and the crucial addi-
tion of PRND in the final framework,27 Global Heath 
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has to be understood as a broader concept in terms of 
content and geographic scope.2 4 Even in the final frame-
work, LMICs only merit one reference,27 and their partic-
ipation in R&I has decreased substantially in the current 
Horizon 2020 programme compared with the EU Frame-
work Programme 7.46 This is also reflected in access to 
EU funding (https:// webgate. ec. europa. eu/ dashboard/ 
sense/ app/ 93297a69- 09fd- 4ef5- 889f- b83c4e21d33e/ 
sheet/ PbZJnb/ state/ analysis) and in contrast to the 
EU’s R&I ‘open to the world policy’.53 Equitable research 
participation is thus still a vision rather than reality.
European industrial competitiveness, innovation and Global 
Health
‘Industrial competitiveness’ is mentioned 14 times and 
‘industry’ 67 times in the Horizon Europe Decision27 as 
well as 13 times in the Regulation28 clearly showing that 
the EU’s paramount concern for R&I is economic. The 
term ‘Global Health’, by contrast, is only mentioned 
three times.27 28 The linking of innovation to industrial 
competitiveness and economic growth27 is problematic, 
as Walsh and colleagues43 pointed out with regard to 
the current R&I programme, Horizon 2020, criticising 
the 'particularly narrow interpretation of the health 
and wealth agenda, regarding health research as a lever 
for economic growth through patentable technological 
advances, exploitable intellectual property and the indus-
trialisation of invention and innovation' (p 669).
Labonté and Gagnon39 point out the danger of health 
inequity through trade and intellectual property rights 
especially for poorer countries. The interests of industry 
and the needs of patients for ‘affordable, cost- effective, 
clinically relevant, user responsive innovations’ (p 1403)54 
differ, and many countries are not in a position to afford 
the latest health technology or innovation.43 54
The pharmaceutical industry has shown little interest 
in developing products regarded as non- profitable, 
such as an investment in new antibiotics (see EU Action 
Plan against AMR 2011, https:// ec. europa. eu/ health/ 
amr/ sites/ amr/ files/ communication_ amr_ 2011_ 748_ 
en. pdf, p 8). This has aggravated the Global Health 
burden in terms of AMR.55 56 The same holds true for 
PRND.57 58 Since 2016, more engagement by pharma-
ceutical and diagnostic companies on AMR research 
has been noticeable following an industry declaration 
(https://www. ifpma. org/ resource- centre/ declaration- 
by- the- pharmaceutical- biotechnology- and- diagnostics- 
industries- on- combating- antimicrobial- resistance/) and 
the emergence of more public–private partnerships 
(https:// acce ssto medi cine foun dation. org/ amr- bench-
mark/ about- the- benchmark/ the- context), many of them 
initiated by the EU59 which has been a major funder 
for PRND.60 The EU has addressed AMR in strategies 
and action plans since 2001 (https://www. eca. europa. 
eu/ lists/ ecadocuments/ ap19_ 03/ ap_ amr_ en. pdf) and 
supported joint African and European research for AMR 
and PRND through the European and Developing Coun-
tries Clinical Trials Partnership (EDCTP) for research 
and product development.61–66 In the 2011 EU action 
plan on AMR, the lack of new antimicrobial agents was 
addressed by launching new programmes under the 
Innovation Medicines Initiative (https:// ec. europa. 
eu/ health/ amr/ sites/ amr/ files/ communication_ amr_ 
2011_ 748_ en. pdf page 9; https://www. imi. europa. eu/), 
the EU’s largest public–private partnership. This initia-
tive has been criticised for its industry- driven research 
agenda and non- transparent decision- making67 68 as well 
as its lack of support to small- sized and medium- sized 
enterprises67 and for the health needs and participation 
of LMICs (https:// eghrin. eu/).
The ‘innovation principle’ of the EU27 is a case in point 
for the dominance of industrial concerns. This ‘principle’ 
has been lobbied for by European companies since 2013 
(https:// corporateeurope. org/ sites/ default/ files/ corpo-
ration_ letter_ on_ innovation_ principle. pdf) and can be 
seen as an attempt by European industries to weaken the 
‘precautionary principle’ (for a definition, see https:// eur- 
lex. europa. eu/ summary/ glossary/ precautionary_ prin-
ciple. html),69 which is mentioned as a guiding principle in 
Horizon Europe.27 Despite the vagueness and ambiguity of 
this term,70 the precautionary principle has safeguarded 
the health of European citizens through, for example, a 
ban on the export of bovine animals from the UK at the 
time of the BSE scandal in the late 1990s (http:// curia. 
europa. eu/ juris/ showPdf. jsf; jsessionid= 9ea7 d0f1 30d6 
a4ba 8562 0a86 4bb1 accc de4f ffad75ac. e34K axiL c3eQ c40L 
axqM bN4P ahaOe0? text=& docid= 101067& pageIndex= 
0& doclang= EN& mode= lst& dir=& occ= first& part= 1& cid= 
303969). For the first time, the industry- backed ‘innovation 
principle’ (defined as ‘whenever precautionary legislation 
is under consideration, the impact on innovation should 
also be taken into full account in the policy and legislative 
process’, see https:// corporateeurope. org/ sites/ default/ 
files/ corporation_ letter_ on_ innovation_ principle. pdf) 
has been incorporated into an EU R&I Framework, 
Horizon Europe, despite civil society and political parties 
alerting to the possibility of increased risks to human 
health and ‘thwarting long- established and settled EU 
environmental principles’ (p 12)69 (https:// corporateeu-
rope. org/ en/ environment/ 2018/ 12/ innovation- prin-
ciple- trap; https://www. greens- efa. eu/ en/ article/ news/ 
the- innovation- principle- is- a- regulatory- trojan- horse- from- 
the- industry/; https:// epha. org/ removing- innovation- 
principle- from- horizon- europe/). The decision to include 
the ‘innovation principle’ therefore raises questions about 
the influence of industry at EU level and whom the EU sees 
as beneficiaries of ‘innovations’. EU initiatives to advance 
needed innovations should operate under the precau-
tionary principle and fulfil responsible R&I requirements 
(https:// ec. europa. eu/ programmes/ horizon2020/ en/ 
h2020- section/ responsible- research- innovation),69 71 both 
of which are mentioned in Horizon Europe.27
Rather than equating the ‘precautionary principle’ with 
thwarting progress and innovation, constraints can stim-
ulate creative solutions as has been shown in LMICs with 
many advancements in health.72 73 EU member states could 
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benefit from these innovations with regard to effective 
and cost- efficient health products, strengthened health 
systems and health information as well as better service 
delivery.72–79 Cost- effectiveness is mentioned in terms of 
tools27 and health systems27 28 in Horizon Europe, and one 
way to advance cost- effective innovations would be for the 
EU to strengthen partnerships between LMICs and HICs 
such as the EDCTP. This programme is an effective part-
nership between African and European health institutes 
in terms of planning and conducting innovative health 
research for PRND and in terms of collaboration and 
joint oversight.64–66 EDCTP has shown success in devel-
oping medicines, vaccines and diagnostics (http://www. 
edctp. org/ web/ app/ uploads/ 2018/ 09/ Tackling- infec-
tious- disease- in- sub- Saharan- Africa_ EDCTP- funded- clin-
ical- studies- for- medical- interventions- 2003- 2018- 4. pdf) 
and could benefit from a higher budget and geographic 
expansion. With a successor programme to the current 
partnership programme being negotiated, the mention of 
Global Health as a possible area for partnership is helpful;28 
however, negotiations for an EU- Africa Global Health Part-
nership increasingly focus on health security, which may 
indicate a shift in the priorities of the EDCTP successor 
programme (Science Business, 20 May 2019; https:// 
sciencebusiness. net/ framework- programmes/ news/ more- 
details- emerge- 44- possible- horizon- europe- partnerships. 
List of candidates for European partnerships available at 
https:// sciencebusiness. net/ sites/ default/ files/ inline- 
files/ HE- partnerships. pdf).
A vISIon for GlobAl HEAlTH rESEArCH
In a global and interlinked world, there is a need for equi-
table,10 well- funded innovative health research between 
LMICs and HICs79 that addresses interconnected health 
issues: climate change; migration; access to food and 
water; the spread of diseases and epidemics; the devel-
opment of new, needed and affordable diagnostics and 
medicines; and the strengthening of health systems to 
significantly decrease the global disease burden49 and 
to improve health equity while ensuring consistency 
between (European) health and trade policies.7 39 80 Such 
R&I could be a catalyst for the implementation of the 
SDGs and a move towards a One Health and eventually a 
Planetary Health approach.6 Global Health research and 
cost- effective solutions would also benefit HICs, such as 
European member states, that increasingly struggle with 
high medicine prices and an overstretched work force, a 
problem well- known to LMICs.73 74 79 In order to devise 
global solutions to global problems, cooperation not only 
needs to involve LMICs but also extend beyond research 
institutions to civil society (eg, NGOs) and governments.4 
This would ensure that key stakeholders have a voice in the 
R&I agenda and facilitate implementation at the national 
level while strengthening a transdisciplinary research 
approach. The equitable cooperation of research insti-
tutes globally is also a crucial element for advancing 
Global Health research, yet should take the key element 
of governance into account.81 This vision of equitable 
research in Global Health supported by the EU is based 
on the Decision document, which foresees improved 
pan- European and regional collaboration.27 Yet, further 
globalisation of this vision is needed to enable institutions 
in LMICs to better access direct funding for health R&I 
and to lead on much needed research in Global Health. 
This could also be achieved through a strengthening and 
widening of the EU partnership programme EDCTP as 
well as Global Health research networks.
ConCluSIon
The discussion and analysis of the proposed Horizon 
Europe R&I Framework by European researchers 
engaged in Global Health confirmed the importance of 
the EU and this framework for health R&I, yet found it 
wanting in terms of a genuine Global Health approach 
despite some improvements to the framework during 
the negotiating process. European industrial interests 
were found to dominate with regard to Global Health 
innovations; LMIC participation, by contrast, is hardly 
mentioned in the framework.
Aluttis and colleagues30 in analysing Global Health 
in relation to the EU remark that ‘the EU remains 
a forceful actor in the world which can speak with a 
strong voice on health matters of global concern’ (p 
6). In order to maintain this role, the EU will need 
to fully embrace the concept of Global Health in the 
implementation of its R&I agenda and facilitate and 
adequately fund joint Global Health research to ensure 
that health innovations benefit all parts of the world. 
Special Horizon Europe funding calls with an intent 
to increase participation of LMIC research institutes 
could directly benefit the EU through effective and 
cost- saving innovations in and from LMICs and their 
transfer to Europe. The EU would therefore benefit 
from strengthening partnership programmes such as 
EDCTP or by facilitating funding for global research 
networks that include research institutions based in 
LMICs and work in a transdisciplinary way with equi-
table governance structures.
Applying a Global Health concept and strategy to 
the framework would show effects beyond health, as 
Speakman and colleagues82 comment: ‘A prominent 
EU Global Health strategy would not only benefit 
Global Health. It would also show leadership from 
Europe, promoting the values of which the EU is justi-
fiably proud: respect for human dignity and human 
rights, freedom, democracy, equality…’ (p e393). An 
enhanced EU strategy on Global Health could help 
invigorate world class health research with tangible 
Global Health outcomes and sustainable Global Health 
innovations for coming generations.
Author affiliations
1Heidelberg Institute of Global Health (HIGH), Heidelberg University, Heidelberg, 
Germany
2Institute for Medical Information Processing, Biometry and Epidemiology, 
Pettenkofer School of Public Health, LMU München, München, Germany
 o
n
 February 20, 2020 by guest. Protected by copyright.
http://gh.bmj.com/
BM
J G
lob Health: first published as 10.1136/bmjgh-2019-001559 on 3 October 2019. Downloaded from 
6 Berner- Rodoreda A, et al. BMJ Global Health 2019;4:e001559. doi:10.1136/bmjgh-2019-001559
BMJ Global Health
3Julius Global Health, Julius Center for Health Sciences and Primary Care, 
University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
4Department of Global Health and Amsterdam Institute for Global Health and 
Development, Amsterdam University Medical Centers, Amsterdam, Netherlands
5Global Health Centre, Centre for Multidisciplinary Research in Health Science 
(MACH), University of Milan, Milan, Italy
6Institute of Global Health, University of Geneva, Geneva, Switzerland
7Barcelona Institute for Global Health (ISGlobal), University of Barcelona, Barcelona, 
Spain
8Division of Infectious Diseases and Tropical Medicine, LMU München, München, 
Germany
9Institute for Global Health, University College London, London, UK
10Institute of Global Health Innovation, Imperial College London, London, UK
11Division of Social Medicine and Global Health, Department of Clinical Sciences, 
Lund University, Malmö, Sweden
12Department of Infectious Diseases, Leiden University Medical Center, Leiden, 
Netherlands
13The George Institute for Global Health, Nuffield Department of Women’s and 
Reproductive Health, University of Oxford, Oxford, UK
14Department of Clinical Sciences, Lund University, Lund, Sweden
15Department of Global Health and Population, Harvard T.H. Chan School of Public 
Health, Boston, Massachusetts, USA
16Africa Health Research Institute (AHRI), Somkhele and Durban, KwaZulu- Natal, 
South Africa
Acknowledgements We would like to thank all participants at the Brussels 
meeting. In particular we would like to express our thanks to Lisa Goerlitz and 
Agustin Martin from Deutsche Stiftung Weltbevölkerung for helpful updates on 
Horizon Europe.
Contributors ABR wrote and revised the manuscript. EAR, FC, NC, GF, JSW, IA, CS, 
AP, RvL and TB conceptualised the Future Search Conference in order to strengthen 
Global Health in the EU Research Agenda. Comments, edits, revisions and final 
approval were provided by EAR, KKG, FC, MR, AF, NC, GF, JSW, IA, HA, AA, LV, CS, AP, 
AJ, RN, RvL, LH and TB.
funding The authors have not declared a specific grant for this research from 
any funding agency in the public, commercial or not- for- profit sectors. TB was 
supported by the Alexander von Humboldt Foundation through the Alexander von 
Humboldt Professor award and by the Federal Ministry of Education and Research, 
the European Commission and the Wellcome Trust.
Competing interests RvL is also chief executive officer and founder of Madam 
Therapeutics, a private entity that is pursuing the development of new antibiotics. 
All other authors declare no known conflict of interest.
patient and public involvement statement Our research did not involve patients. 
NGO representatives collaborated with European Global Health researchers in 
critically assessing the Horizon Europe Framework with a view to strengthen Global 
Health and Global Health Research and to ensure that the new Framework does not 
only benefit EU, but global citizens.
patient consent for publication Not required.
Ethics approval Not required.
provenance and peer review Not commissioned; externally peer reviewed.
data availability statement The authors confirm that the data supporting the 
findings of this article are available within the article.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the 
use is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
orCId id
Astrid Berner- Rodoreda http:// orcid. org/ 0000- 0002- 5484- 890X
ReFeRences
 1 Winslow CE. The untilled fields of public health. Science 
1920;51:23–33.
 2 Koplan JP, Bond TC, Merson MH, et al. Towards a common 
definition of global health. The Lancet 2009;373:1993–5.
 3 Macfarlane SB, Jacobs M, Kaaya EE. In the name of global 
health: trends in academic institutions. J Public Health Policy 
2008;29:383–401.
 4 Wernli D, Tanner M, Kickbusch I, et al. Moving global health forward 
in academic institutions. J Glob Health 2016;6:153–8.
 5 Beaglehole R, Bonita R. What is global health? Glob Health Action 
2010;3. doi:10.3402/gha.v3i0.5142. [Epub ahead of print: 06 Apr 
2010].
 6 Havemann M, Bösner S. Global Health as "umbrella term" - a 
qualitative study among Global Health teachers in German medical 
education. Global Health 2018;14:32.
 7 Kickbusch I. The need for a European strategy on global health. 
Scand J Public Health 2006;34:561–5.
 8 Kickbusch I, Buse K. Global influences and global responses: 
international health at the turn of the twenty- first century. In: 
Merson MH, Black RE, Mills AJ, eds. International public health: 
diseases, programs, systems, and policies. Gaithersburg, MD: Aspen 
Publishers, 2001: 701–38.
 9 Merson MH, Black RE, Mills AJ. Global health. Burlington, MA: 
Jones & Bartlett Publishers, 2011: 966.
 10 Gautier L, Sieleunou I, Kalolo A. Deconstructing the notion of "global 
health research partnerships" across Northern and African contexts. 
BMC Med Ethics 2018;19(Suppl 1):49.
 11 Jupp S. Global forum for health research, forum 2009: innovating for 
the health of all. MEDICC Rev 2010;12:5-7.
 12 Crane JT. Unequal ‘Partners’. AIDS, Academia, and the Rise of 
Global Health. Behemoth 2010;3.
 13 Abubakar I, Aldridge RW, Devakumar D, et al. The UCL–Lancet 
Commission on migration and health: the health of a world on the 
move. The Lancet 2018;392:2606–54.
 14 Hanefeld J, Vearey J, Lunt N, et al. A global research agenda on 
migration, mobility, and health. The Lancet 2017;389:2358–9.
 15 Choi BC, Pak AW. Multidisciplinarity, interdisciplinarity and 
transdisciplinarity in health research, services, education and policy: 
1. Definitions, objectives, and evidence of effectiveness. Clin Invest 
Med 2006;29:351–64.
 16 Manne- Goehler J, Atun R, Stokes A, et al. Diabetes diagnosis and 
care in sub- Saharan Africa: pooled analysis of individual data from 
12 countries. Lancet Diabetes Endocrinol 2016;4:903–12.
 17 Bärnighausen T. Population health intervention research: three 
important advancements. Int J Public Health 2017;62:841–3.
 18 Janoff S, Weisbord M. Future Search as ‘real- time’ action research. 
Futures 2006;38:716–22.
 19 Weisbord M, Janoff S. Future search: an action guide to finding 
common ground in organizations and communities. Berrett- Koehler 
Publishers, 2000: 294.
 20 Weisbord MR. Future search: innovative business conference. 
Planning Review 1984;12:16–20.
 21 European Commission. Proposal for a Decision of the European 
Parliament and of the Council on establishing the specific 
programme implementing Horizon Europe – the Framework 
Programme for Research and Innovation, 7.6.2018. Available: 
https:// eur- lex. europa. eu/ resource. html? uri= cellar: 7cc790e8- 6a33- 
11e8- 9483- 01aa75ed71a1. 0002. 03/ DOC_ 1& format= PDF
 22 European Commission. Annexes to the Proposal for a Decision 
of the European Parliament and of the Council establishing 
the specific programme implementing Horizon Europe – the 
Framework Programme for Research and Innovation, 7.6.2018. 
Available: https:// eur- lex. europa. eu/ resource. html? uri= cellar: 
7cc790e8- 6a33- 11e8- 9483- 01aa75ed71a1. 0002. 03/ DOC_ 2& 
format= PDF
 23 European Commission. Proposal for a Regulation of the European 
Parliament and of the Council establishing Horizon Europe – the 
Framework Programme for Research and Innovation laying down its 
rules for participation and dissemination, 7.6.2018. Available: https:// 
eur- lex. europa. eu/ resource. html? uri= cellar: b8518ec6- 6a2f- 11e8- 
9483- 01aa75ed71a1. 0001. 03/ DOC_ 1& format= PDF
 24 European Commission. Annexes to the Proposal for a Regulation 
of the European Parliament and of the Council establishing Horizon 
Europe - the Framework Programme for Research and Innovation, 
laying down its rules for participation and dissemination, 7.6.2018. 
Available: https:// eur- lex. europa. eu/ resource. html? uri= cellar: 
b8518ec6- 6a2f- 11e8- 9483- 01aa75ed71a1. 0001. 03/ DOC_ 2& format= 
PDF
 25 Council of the European Union. Interinstitutional file: 2018/0224, 
15102/18. Proposal for a Regulation of the European Parliament 
and of the Council establishing Horizon Europe – the Framework 
Programme for Research and Innovation, laying down its rules for 
participation and dissemination- Partial general approach, 3.12.2018. 
 o
n
 February 20, 2020 by guest. Protected by copyright.
http://gh.bmj.com/
BM
J G
lob Health: first published as 10.1136/bmjgh-2019-001559 on 3 October 2019. Downloaded from 
Berner- Rodoreda A, et al. BMJ Global Health 2019;4:e001559. doi:10.1136/bmjgh-2019-001559 7
BMJ Global Health
Available: https:// data. consilium. europa. eu/ doc/ document/ ST- 
15102- 2018- INIT/ en/ pdf
 26 European Parliament. Amendments adopted by the European 
Parliament on 12 December 2018 on the Proposal for a Decision 
of the European Parliament and of the Council on establishing 
the specific programme implementing Horizon Europe - the 
Framework Programme for Research and Innovation. Available: 
http://www. europarl. europa. eu/ doceo/ document/ TA- 8- 2018- 0510_ 
EN. html
 27 Council of the European Union. Interinstitutional file: 2018/0225, 
8550/19. Proposal for a Decision of Council on establishing the 
specific programme implementing Horizon Europe - the Framework 
Programme for Research and Innovation - Partial general approach, 
15.4.2019. Available: https:// data. consilium. europa. eu/ doc/ 
document/ ST- 8550- 2019- INIT/ en/ pdf
 28 Council of the European Union. Interinstitutional File: 2018/0224, 
7942/19. Proposal for a Regulation of the European Parliament 
and of the Council establishing Horizon Europe - the Framework 
Programme for Research and Innovation, laying down its rules 
for participation and dissemination - Common understanding., 
27.3.2019. Available: https://www. consilium. europa. eu/ media/ 
38902/ st07942- en19. pdf
 29 United Nations General Assembly. Transforming our world: the 2030 
agenda for sustainable development. New York: United Nations 
General Assembly, 2015.
 30 Aluttis C, Krafft T, Brand H. Global health in the European Union-
-a review from an agenda- setting perspective. Glob Health Action 
2014;7:23610–6.
 31 Council of the European Union. Council conclusions on the EU role 
in global health, 2010. Available: https:// ec. europa. eu/ europeaid/ 
council- conclusions- eu- role- global- health_ en
 32 Steurs L, Van de Pas R, Delputte S, et al. The global health policies 
of the EU and its member states: a common vision? Int J Health 
Policy Manag 2017;7:433–42.
 33 European Commission. Communication from the Commission to 
the Council, the European Parliament, the European Economic and 
Social Commitee and the Committee of the Regions. The EU role in 
global health. Brussels; 2010. (com). Available: https:// ec. europa. eu/ 
europeaid/ sites/ devco/ files/ communication- eu- role- in- global- health- 
com2010128- 20100331_ en. pdf
 34 European Parliament and Council. Regulation (EU) No 1291/2013 of 
the European Parliament and of the Council of 11 December 2013 
establishing Horizon 2020 - the Framework Programme for Research 
and Innovation (2014-2020) and repealing Decision No 1982/2006/
EC. 
. Available: https:// ec. europa. eu/ research/ participants/ data/ ref/ 
h2020/ legal_ basis/ fp/ h2020- eu- establact_ en. pdf
 35 Rushton S. Global health security: Security for whom? Security from 
what? Polit Stud 2011;59:779–96.
 36 Steurs L, van de Pas R, Decoster K, et al. Role of the European 
Union in global health. Lancet Glob Health 2017;5:e756.
 37 Aldis W. Health security as a public health concept: a critical 
analysis. Health Policy Plan 2008;23:369–75.
 38 Baldwin DA. The concept of security. Rev Int Stud 1997;23:5–26.
 39 Labonté R, Gagnon ML. Framing health and foreign policy: lessons 
for global health diplomacy. Glob Health 2010;6:14.
 40 European Commission. Europe 2020 a strategy for smart, 
sustainable and inclusive growth. Brussels, 2010. Available: http:// 
ec. europa. eu/ eu2020/ pdf/ COMPLET% 20EN% 20BARROSO% 20% 
20% 20007% 20-% 20Europe% 202020% 20-% 20EN% 20version. pdf
 41 Kickbusch I, Franz C, Holzscheiter A, et al. Germany's expanding 
role in global health. The Lancet 2017;390:898–912.
 42 Yamey G, Campe S, Fewer S. Germany, the G7, and global health. 
BMJ 2015;350.
 43 Walshe K, McKee M, McCarthy M, et al. Health systems and policy 
research in Europe: Horizon 2020. The Lancet 2013;382:668–9.
 44 European Parliament. Amendments by the European Parliament to 
the Commission Proposal. Proposal for a Regulation (EU) 2019/ of 
the European Parliament and of the Council - establishing Horizon 
Europe – the Framework Programme for Research and Innovation, 
laying down its rules for participation and dissemination. 2019.
 45 European Commission. Statement by Commissioner Moedas on 
the European Parliament’s vote on Horizon Europe, 2019. Available: 
http:// europa. eu/ rapid/ press- release_ STATEMENT- 19- 2163_ en. htm
 46 European Commission. Commission staff working document. Interim 
Evaluation of Horizon 2020. Annex I, 29.5.2017. Available: http:// ec. 
europa. eu/ research/ evaluations/ pdf/ archive/ h2020_ evaluations/ swd( 
2017) 221- annex- 1- interim_ evaluation- h2020. pdf [Accessed 13 Feb 
2019].
 47 European Union. EU Budget for the Future - Horizon Europe - EU 
Funding for Research and Innovation 2021-2027, 2018. Available: 
https:// ec. europa. eu/ commission/ sites/ beta- political/ files/ budget- 
proposals- research- innovation- may2018_ en. pdf
 48 Målqvist M. Community agency and empowerment- a need for 
new perspectives and deepened understanding. Ups J Med Sci 
2018;123:123–30.
 49 WHO. World Health Statistics Overview 2019 - Monitoring Health for 
the SDGs, 2019. Available: https://www. who. int/ gho/ publications/ 
world_ health_ statistics/ 2019/ EN_ WHS_ 2019_ Main. pdf
 50 Koivusalo M. The state of health in all policies (HiAP) in the European 
Union: potential and pitfalls. J Epidemiol Community Health 
2010;64:500–3.
 51 Buse K, Hawkes S. Health in the sustainable development goals: 
ready for a paradigm shift? Glob Health 2015;11.
 52 Matthiessen L, Bergström R, Dustdar S, et al. Increased momentum 
in antimicrobial resistance research. The Lancet 2016;388.
 53 European Commission. Implementation of the strategy for 
International Cooperation in Research & Innovation, 2016.
 54 Lehoux P, Miller FA, Daudelin G. Horizon 2020 and the need 
to reinvent health technology development. The Lancet 
2013;382:1402–3.
 55 Monnet DL. Antibiotic development and the changing role of the 
pharmaceutical industry. Int J Risk Safe Med 2005;17:133–45 
https://www. reactgroup. org/ uploads/ react/ resources/ 101/ 
Antibiotic% 20development% 20and% 20the% 20changing% 20role% 
20of% 20the% 20pharmaceutical% 20industry. en. 156. pdf
 56 O’Neill J. Tackling drug- resistant infections globally: final report and 
recommendations. The review on antimicrobial resistance, 2016. 
Available: https:// amr- review. org/ sites/ default/ files/ 160518_ Final% 
20paper_ with% 20cover. pdf
 57 Aerts C, Sunyoto T, Tediosi F, et al. Are public- private partnerships 
the solution to tackle neglected tropical diseases? A systematic 
review of the literature. Health Policy 2017;121:745–54.
 58 von Philipsborn P, Steinbeis F, Bender ME, et al. Poverty- related and 
neglected diseases – an economic and epidemiological analysis of 
poverty relatedness and neglect in research and development. Glob 
Health Action 2015;8.
 59 van Hengel AJ, Marin L. Research, innovation, and policy: an 
alliance combating antimicrobial resistance. Trends Microbiol 
2019;27:287–9.
 60 European Commission. Evaluation of the impact of the European 
Union’s research funding for poverty- related and neglected 
diseases : lessons from EU research funding (1998–2013), 2017. 
Available: https:// publications. europa. eu/ en/ publication- detail/-/ 
publication/ 1f324128- a4c1- 11e7- 837e- 01aa75ed71a1/ language- en 
[Accessed 13 Feb 2019].
 61 Bronzwaer S, Lönnroth A, Haigh R. The European community 
strategy against antimicrobial resistance. Euro Surveill 2004;9:30–4.
 62 European Commission. A European one health action plan against 
antimicrobial resistance, 2017. Available: https:// ec. europa. eu/ 
health/ amr/ sites/ amr/ files/ amr_ action_ plan_ 2017_ en. pdf
 63 Chinnock P. EDCTP high- level meeting moving forward and 
consolidating gains for an EDCTP successor programme, Lisbon, 
Portugal, 17 September 2018. Rotterdam, 2018. Available: http://
www. edctp. org/ web/ app/ uploads/ 2018/ 12/ EDCTP- High- level- 
meeting- Lisbon- report- final. pdf
 64 Olesen OF. European & Developing Countries Clinical Trials 
Partnership (EDCTP). Hum Vaccin Immunother 2018;14:14–16.
 65 Zumla A, Petersen E, Nyirenda T, et al. Tackling the tuberculosis 
epidemic in sub- Saharan Africa- unique opportunities arising 
from the second European Developing Countries Clinical Trials 
Partnership (EDCTP) programme 2015-2024. Int J Infect Dis 
2015;32:46–9.
 66 Matee MI, Manyando C, Ndumbe PM, et al. European and 
developing countries clinical trials partnership (EDCTP): the path 
towards a true partnership. BMC Public Health 2009;9:249.
 67 European Commission. The Interim Evaluation of the Innovative 
Medicines Initiative 2 Joint Undertaking (2014-2016) operating under 
Horizon 2020 - Experts Group Report, 2017. Available: https:// 
publications. europa. eu/ en/ publication- detail/-/ publication/ 13dc2f27- 
ae3b- 11e7- 837e- 01aa75ed71a1/ language- en
 68 Galsworthy MJ, Palumbo L, McKee M. Has big pharma hijacked the 
European health research budget? The Lancet 2014;383.
 69 Garnett K, Van Calster G, Reins L. Towards an innovation principle: 
an industry trump or shortening the odds on environmental 
protection? Law Innov Technol 2018;10:1–14.
 70 Garnett K, Parsons DJ. Multi- Case review of the application of the 
precautionary principle in European Union law and case law. Risk 
Anal 2017;37:502–16.
 71 von Schomberg R. A vision of responsible research and innovation. 
In: Owen R, Bessant J, Heintz M, eds. Responsible innovation. 
Chichester, UK: John Wiley & Sons, Ltd, 2013: 51–74.
 o
n
 February 20, 2020 by guest. Protected by copyright.
http://gh.bmj.com/
BM
J G
lob Health: first published as 10.1136/bmjgh-2019-001559 on 3 October 2019. Downloaded from 
8 Berner- Rodoreda A, et al. BMJ Global Health 2019;4:e001559. doi:10.1136/bmjgh-2019-001559
BMJ Global Health
 72 Abubakar I, Plasencia A, Bärnighausen T, et al. Horizon Europe: 
towards a European agenda for global health research and 
innovation. The Lancet 2019;393:1272–3.
 73 Syed SB, Dadwal V, Rutter P, et al. Developed- developing country 
partnerships: Benefits to developed countries? Glob Health 
2012;8:17.
 74 Bhattacharyya O, Wu D, Mossman K, et al. Criteria to assess 
potential reverse innovations: opportunities for shared learning 
between high- and low- income countries. Global Health 2017;13:4.
 75 DePasse JW, Lee PT. A model for ‘reverse innovation’ in health care. 
Glob Health 2013;9:40.
 76 Govindarajan V, Ramamurti R. Reverse innovation, emerging 
markets, and global strategy. Glob Strategy J 2011;1:191–205.
 77 Ibe CA, Basu L, Gooden R, et al. From Kisiizi to Baltimore: cultivating 
knowledge brokers to support global innovation for community 
engagement in healthcare. Global Health 2018;14:19.
 78 Simula H, Hossain M, Halme M. Frugal and reverse innovations 
– Quo Vadis? [Internet]. Rochester, NY: Social Science Research 
Network, 2015. https:// papers. ssrn. com/ abstract= 2678861
 79 Binagwaho A, Nutt CT, Mutabazi V, et al. Shared learning in an 
interconnected world: innovations to advance global health equity. 
Global Health 2013;9:37.
 80 Walls H, Baker P, Parkhurst J. Addressing trade policy as a macro- 
structural determinant of health: The role of institutions and ideas. 
Glob Soc Policy 2018;18:94–101.
 81 Shiffman J. Four challenges that global health networks face. Int J 
Health Policy Manag 2017;6:183–9.
 82 Speakman EM, McKee M, Coker R. If not now, when? Time for 
the European Union to define a global health strategy. Lancet Glob 
Health 2017;5:e392–3.
 o
n
 February 20, 2020 by guest. Protected by copyright.
http://gh.bmj.com/
BM
J G
lob Health: first published as 10.1136/bmjgh-2019-001559 on 3 October 2019. Downloaded from 
